We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. SCOTTSDALE, Ariz. — A novel therapeutic approach ...
Both complement inhibitors and neonatal Fc receptor blockers led to improvements in symptoms, according to a meta-analysis. A new review of the latest therapies for myasthenia gravis (MG), including ...
MedPage Today on MSN
FcRn Inhibitors Play an Evolving Role in Myasthenia Gravis Treatment
Three agents are approved, and more studies are underway ...
Autoimmune drug development increasingly recognizes that the Fc-FcR axis is more than an effector mechanism; it is a controllable immunological node that bridges humoral and cellular responses. This ...
Please provide your email address to receive an email when new articles are posted on . FcRn receptors have received FDA approvals in generalized myasthenia gravis. Studies of FcRn receptors in RA and ...
As key molecules on the surface of immune cells, Fc receptors are the core hub of antibody-mediated effector functions. They play an irreplaceable role in physiological processes such as ...
Viridian Therapeutics Inc. has disclosed a preclinical portfolio of neonatal Fc receptor (FcRn) inhibitors designed for next-generation treatment of antibody-mediated autoimmune diseases.
A research team of the University Medical Center Mainz has succeeded in observing for the first time how G protein-coupled receptors in living cells actually respond to activating substances. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results